
|Articles|February 1, 2002
Novel vaccine promising in treatment of genital warts
Baltimore - Phase II study results point to the potential roleof HspE7 as a safe and effective immunotherapeutic agent for the treatmentof genital warts and other HPV-related sexually transmitted diseases, KeertiV. Shah, M.D., said.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Envudeucitinib Achieves 54% PASI 100 Rate at 48 Weeks in Phase 3 Extension
2
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
3
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











